



Publications approval reference: C1460

Patient Group Direction for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

This Patient Group Direction (PGD) is for the administration of COVID-19 mRNA vaccine BNT162b2 to individuals in accordance with the national COVID-19 vaccination programme.

This PGD is for the administration of COVID-19 mRNA vaccine BNT162b2 by registered healthcare practitioners identified in [Section 3](#).

The national COVID-19 vaccination programme may also be provided under national protocol or on a patient specific basis (that is by or on the direction of an appropriate independent prescriber). Supply and administration in these instances are not covered by this PGD.

Reference no: COVID-19 mRNA vaccine BNT162b2 PGD
Version no: v06.00
Valid from: 19 November 2021
Expiry date: 31 March 2022

The UK Health Security Agency (UKHSA) has developed this PGD for authorisation by NHS England and NHS Improvement (NHSEI) to facilitate the delivery of the national COVID-19 vaccination programme.

NHSEI and those providing services in accordance with this PGD must not alter, amend or add to the clinical content of this document (sections 3, 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. [Section 2](#) may be amended only by the person(s) authorising the PGD, in accordance with Human Medicines Regulations 2012 (HMR2012)¹ [Schedule 16 Part 2](#), on behalf of NHSEI. [Section 7](#) is to be completed by registered practitioners providing the service and their authorising/line manager.

Operation of this PGD is the responsibility of NHSEI and service providers. The final authorised copy of this PGD should be kept by NHSEI for 25 years after the PGD expires. Provider organisations adopting authorised versions of this PGD should also retain copies for the period specified above.

Individual registered practitioners must be authorised by name to work according to the current version of this PGD by signing section 7. A manager with the relevant level of authority should also provide a counter signature, unless there are contractual arrangements for self-declaration.

Providers must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of PHE/UKHSA developed COVID-19 vaccine PGDs can be found via: [COVID-19 vaccination programme - GOV.UK \(www.gov.uk\)](#)

The most current national recommendations should be followed. This may mean that a Patient Specific Direction (PSD) is required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD. Any concerns regarding the content of this PGD should be addressed to: immunisation@phe.gov.uk

¹ This includes any relevant amendments to legislation (such as [2013 No.235](#), [2015 No.178](#), [2015 No.323](#) and [2020 No.1125](#)).

Change history




| Version | Change details | Date |
|-----------------------------------|--|------------|
| V01.00 | New PHE PGD template for COVID-19 mRNA vaccine BNT162b2. | 10/12/2020 |
| V02.00 | COVID-19 mRNA vaccine BNT162b2 PGD V01.00 amended to: <ul style="list-style-type: none"> • mention consent, or 'best-interests' decision in accordance with the Mental Capacity Act 2005 • footnote that carers are included in priority group 6 • update criteria for exclusion and cautions pertaining to anaphylaxis • remove criteria for exclusion and update caution relating to past history of COVID-19 infection • define minimum dose interval and vaccination in accordance with national recommendations • update advice for women of childbearing age and remove requirement to avoid pregnancy until 2 months after the second dose of vaccine • allow for vaccination of breastfeeding women • allow for administration of a sixth dose if obtainable from the multidose vial • update supplies section to order via the national appointed supply route for the provider | 02/01/2021 |
| V03.00 | COVID-19 mRNA vaccine BNT162b2 PGD V02.00 amended to: <ul style="list-style-type: none"> • identify the national protocol or patient specific provision as an alternative to use of this PGD • cover Joint Committee on Vaccination and Immunisation (JCVI) recommendations for phase 2 • include vaccination in pregnancy in accordance with the Green Book Chapter 14a, remove additional information on pregnancy and in cautions refer to Chapter 14a and the Royal College of Obstetricians and Gynaecologists (RCOG) decision aid • include JCVI advice for homelessness and detained settings • update of criteria for exclusion, cautions and actions if excluded which pertain to anaphylaxis, allergy and reactions to 1st dose • move participation in a clinical trial from the criteria for exclusion section to the caution section • move recommendations for individuals with bleeding disorder to the cautions section • clarify under Name, strength and formulation of drug section that the PGD may be used to administer vaccine that has been pre-prepared in accordance with the manufacturer's instructions and HMR2012 Regulation 3A • include a paragraph in the legal category section to allow for PGD use to continue should it be provided a marketing authorisation in the future, so long as the PGD remains clinically appropriate • reword advice pertaining to the extraction of full doses from a vial and not pooling excess vaccine • remove specific reference to supply via ImmForm • remove detail on management of anaphylaxis which is outside the required scope of this PGD • update key references • remove Appendix A and refer directly to the Green Book Chapter 14a | 17/03/2021 |
| V04.00 Continued over page | COVID-19 mRNA vaccine BNT162b2 PGD V03.00 amended to: <ul style="list-style-type: none"> • include requirement to have undertaken training to meet the minimum standards in relation to vaccinating those under 18 | 06/08/2021 |

| | | |
|-------------------------------|---|-------------------|
| <p>V04.00 (continued)</p> | <ul style="list-style-type: none"> • criteria for inclusion updated to include: <ul style="list-style-type: none"> ○ those aged from 12 years of age with specific underlying health conditions that put them at risk of serious COVID-19 or who expect to share living accommodation with individuals who are immunosuppressed ○ those aged 16 and 17 years of age who are frontline health and social care workers or in an at-risk group ○ other individuals aged 16 and 17 years of age who may receive one dose only • criteria for exclusion amended from 16 to 12 years of age • note under criteria for exclusion specifying individuals aged 16 and 17 years of age who are not frontline health and social care workers, or who are not in an at-risk group, are currently eligible for one dose only • additional information under Cautions regarding pregnancy and Guillain-Barre Syndrome • dose and frequency of administration updated to reflect recent JCVI and Green Book Chapter 14a advice including dose intervals and one dose only for those aged 16 and 17 who are not frontline health and social care workers, or who are not in an at-risk group • addition one dose only for those aged 16 and 17 who are not frontline health and social care workers, or who are not in an at-risk group to the quantity to be supplied / administered • addition regarding dose intervals with shingles vaccine to drug interactions • addition of myocarditis and pericarditis to identification and management of adverse reactions • Under Special considerations / additional information new information on: <ul style="list-style-type: none"> ○ previous incomplete vaccination ○ individuals vaccinated abroad ○ co-administration with other vaccines ○ non-responders and immunosuppression • minor wording changes and additions to standard text for consistency; updated references | |
| <p>V05.00</p> | <p>COVID-19 mRNA vaccine BNT162b2 PGD V04.00 amended to:</p> <ul style="list-style-type: none"> • remove specific reference to clinically extremely vulnerable (CEV) individuals as they are covered by the inclusion of those in at risk groups • include individuals aged 12 years to under 16 years of age who are in an at-risk group (see the table 'Clinical risk groups for children aged 12-15 years' in Chapter 14a) • include other individuals from age 12 years to under 18 years of age, who do not meet any of the other criteria for inclusion, as eligible for their first dose of the COVID-19 vaccine only • include individuals referred for a third primary dose of COVID-19 vaccine in accordance with patient specific recommendations from their specialist, GP or prescriber • include individuals eligible for a booster (third) dose as part of the national COVID-19 vaccination programme • exclude individuals who have experienced myocarditis or pericarditis determined as likely to be related to previous COVID-19 vaccination • move cautions relating to pregnancy and those involved in clinical trials to the additional information section • update to cautions • update the additional information on immunosuppressed individuals, co-administration and incomplete vaccination • remove key references to JCVI statements which are now incorporated into the guidance in Chapter 14a • minor wording changes and additions to text for consistency; updated references | <p>17/09/2021</p> |

| | | |
|--------|--|------------|
| V06.00 | <p>COVID-19 mRNA vaccine BNT162b2 PGD V05.00 amended to:</p> <ul style="list-style-type: none"> • include second dose for individuals 16 and 17 years of age • reword criteria for inclusion • reword criteria for exclusion pertaining to allergic reactions • update cautions in line with revisions to Chapter 14a • re-write dose and frequency of administration section, to identify preferred 12-week interval for those under 18 years of age and not in a risk group, to include a paragraph on minimum intervals post COVID-19 infection and to include minimum intervals for booster vaccination • include the international non-proprietary name (INN) tozinameran • update shelf life from 6 to 9 months • update Special considerations/additional information section in line with revisions to Chapter 14a • include Appendix A • minor wording changes and additions to text for consistency and to rebrand from PHE to UKHSA; updated references | 18/11/2021 |
|--------|--|------------|

1. PGD development

This PGD has been developed by the following health professionals on behalf of the UKHSA:

| Developed by: | Name | Signature | Date |
|--|--|--|------------|
| Pharmacist (Lead Author) | Elizabeth Graham Lead Pharmacist Immunisation Services, Immunisation and Vaccine Preventable Diseases Division, UKHSA |  | 18/11/2021 |
| Doctor | Mary Ramsay Consultant Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA |  | 18/11/2021 |
| Registered Nurse (Chair of Expert Panel) | David Green Nurse Consultant, Immunisation and Vaccine Preventable Diseases Division, UKHSA |  | 18/11/2021 |

In addition to the signatories above the working group included:

| Name | Designation |
|----------------|--|
| Jane Horsfall | Senior Policy Manager, Primary Care Group, NHSEI |
| Jo Jenkins | Specialist Pharmacist (Patient Group Directions), NHS Specialist Pharmacy Service |
| Jill Loader | Deputy Director, Primary Care Group, NHSEI |
| Naveen Dosanjh | Senior Clinical Advisor – Pharmacy, Clinical Workstream (COVID-19 Vaccination Programme), NHSEI |
| Gul Root | Principal Pharmaceutical Officer, Department of Health and Social Care and National lead pharmacy public health, Office for Health Improvement and Disparities |

This PGD has been peer reviewed by the UKHSA Immunisations PGD Expert Panel in accordance with the UKHSA PGD Policy. It has been ratified by the UKHSA Medicines Governance Group and the UKHSA Quality and Clinical Governance Delivery Board.

Expert Panel

| Name | Designation |
|---------------------|--|
| Nicholas Aigbogun | Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA |
| Sarah Dermont | Clinical Project Coordinator and Registered Midwife, NHS Infectious Diseases in Pregnancy Screening Programme, NHSEI |
| Ed Gardner | Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead |
| Michelle Jones | Principal Medicines Optimisation Pharmacist, NHS Bristol North Somerset and South Gloucestershire CCG |
| Jacqueline Lamberty | Lead Pharmacist Medicines Governance Services, UKHSA |
| Vanessa MacGregor | Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA |


| | |
|------------------|---|
| Alison Mackenzie | Consultant in Public Health Medicine, Screening and Immunisation Lead NHSEI South (South West) |
| Gill Marsh | Principal Screening and Immunisation Manager, Public Health England / NHSEI (North West) |
| Lesley McFarlane | Screening and Immunisation Manager: Clinical (COVID-19 and Influenza), NHSEI (Midlands) |
| Tushar Shah | Lead Pharmacy Advisor, NHSEI (London Region) |

2. Organisational authorisation

The PGD is not legally valid until it has had the relevant organisational authorisation from NHSEI completed below.

NHSEI accepts governance responsibility for this PGD. Any provider delivering the national COVID-19 vaccination programme under PGD must work strictly within the terms of this PGD, relevant NHS standard operating procedures (SOPs) and contractual arrangements with the commissioner for the delivery of the national COVID-19 vaccination programme.

NHSEI authorises this PGD for use by the services or providers delivering the national COVID-19 vaccination programme.

| Organisational approval (legal requirement) | | | |
|---|--------------------------|--|------------------|
| Role | Name | Sign | Date |
| Medical Director, COVID-19 Vaccination Programme, NHSEI | Dr Jonathan Leach OBE |  | 19 November 2021 |

[Section 7](#) provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation records, specifying the PGD and version number, may be used where appropriate in accordance with local policy. This may include the use of electronic records.

Assembly, final preparation and administration of vaccines supplied and administered under this PGD must be subject to NHS governance arrangements and standard operating procedures that ensure that the safety, quality or efficacy of the product is not compromised. The assembly, final preparation and administration of the vaccines must also be in accordance with the instructions for usage that are conditions of the authorisation to supply the product. These conditions for usage are in the Information for UK Healthcare Professionals, published alongside the conditions of authorisation and available at:

[Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19)

3. Characteristics of staff

| | |
|--|---|
| <p>Qualifications and professional registration</p> | <p>Practitioners must only work under this PGD where they are competent to do so. Practitioners working to this PGD must also be one of the following registered professionals who can legally supply and administer under a PGD (see Patient Group Directions: who can administer them):</p> <ul style="list-style-type: none"> • nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) • pharmacists currently registered with the General Pharmaceutical Council (GPhC) • chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC) • dental hygienists and dental therapists registered with the General Dental Council • optometrists registered with the General Optical Council. <p>Practitioners must also fulfil all of the Additional requirements.</p> |
| <p>Additional requirements</p> | <p>Additionally, practitioners:</p> <ul style="list-style-type: none"> • must be authorised by name as an approved practitioner under the current terms of this PGD before working to it • must have undertaken appropriate training for working under PGDs for supply/administration of medicines • must be competent in the use of PGDs (see NICE Competency framework for health professionals using PGDs) • must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), should it become licensed, or the Regulation 174 Information for UK Healthcare Professionals for the vaccine and familiar with the national recommendations for the use of this vaccine • must be familiar with, and alert to changes in relevant chapters of Immunisation Against Infectious Disease: the Green Book • must be familiar with, and alert to changes in the relevant NHS Standard Operating Procedures (SOPs) and commissioning arrangements for the national COVID-19 vaccination programme • must have undertaken training appropriate to this PGD as required by local policy and SOPs and in line with the Training recommendations for COVID-19 vaccinators. • must have undertaken training to meet the minimum standards in relation to vaccinating those under 18 as required by national and local policy. • must have completed the national COVID-19 vaccination e-learning programme, including the relevant vaccine specific session, and/or locally-provided COVID-19 vaccine training • must be competent to assess individuals for suitability for vaccination, identify any contraindications or precautions, obtain informed consent (or 'best interests' decision in accordance with the Mental Capacity Act 2005) and to discuss issues related to vaccination. For further information on consent see Chapter 2 of 'The Green Book'. • must be competent in the correct handling and storage of vaccines, and management of the cold chain • must be competent in the handling of the vaccine product, procedure for dilution of the vaccine and use of the correct technique for drawing up the correct dose |

Continued over page

| | |
|---|---|
| <p>Additional requirements (continued)</p> | <ul style="list-style-type: none"> • must be competent in the intramuscular injection technique • must be competent in the recognition and management of anaphylaxis, have completed basic life support training and be able to respond appropriately to immediate adverse reactions • must have access to the PGD and relevant COVID-19 vaccination programme online resources such as the Green Book and COVID-19 vaccination programme: Information for healthcare practitioners • must have been signed off as competent using the COVID-19 vaccinator competency assessment tool if new to or returning to immunisation after a prolonged period (more than 12 months) or have used the tool for self-assessment if experienced vaccinator (vaccinated within past 12 months) • should fulfil any additional requirements defined by local or national policy <p>The individual practitioner must be authorised by name, under the current version of this PGD before working according to it.</p> |
| <p>Continued training requirements</p> | <p>Practitioners must ensure they are up to date with relevant issues and clinical skills relating to vaccination and management of anaphylaxis.</p> <p>Practitioners should be constantly alert to any subsequent recommendations from the UKHSA and/or NHSEI and other sources of medicines information.</p> |

4. Clinical condition or situation to which this PGD applies

| | |
|---|---|
| Clinical condition or situation to which this PGD applies | <p>COVID-19 mRNA vaccine BNT162b2 is indicated for the active immunisation of individuals for the prevention of coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus, in accordance with the national COVID-19 vaccination programme (see COVID-19 vaccination programme page) and recommendations given in Chapter 14a of the Immunisation Against Infectious Disease: the 'Green Book', and subsequent correspondence/publications from the UKHSA and/or NHSEI.</p> |
| Criteria for inclusion | <p>COVID-19 mRNA vaccine BNT162b2 should be offered to all individuals aged 12 years and over in accordance with the recommendations in Chapter 14a of the Green Book.</p> <p>Individuals are eligible for different dose schedules based on their age and recognised risk group (see the Dose and frequency of administration section).</p> |
| Criteria for exclusion² | <p>Individuals for whom valid consent, or 'best-interests' decision in accordance with the Mental Capacity Act 2005, has not been obtained (for further information on consent see Chapter 2 of 'The Green Book'). The Regulation 174 Information for UK recipients for COVID-19 mRNA vaccine BNT162b2 should be available to inform consent.</p> <p>Individuals who:</p> <ul style="list-style-type: none"> • are less than 12 years of age • have had a previous systemic allergic reaction (including immediate onset anaphylaxis) to a previous dose of a COVID-19 mRNA vaccine or to any component or residue of the manufacturing process³ in the COVID-19 mRNA vaccine BNT162b2 • have a history of prior allergic reaction to COVID-19 vaccine that required medical intervention in hospital • have a history of immediate anaphylaxis to multiple, different drug classes, with the trigger unidentified (this may indicate polyethylene glycol (PEG) allergy) • have a history of anaphylaxis to a vaccine, injected antibody preparation or a medicine likely to contain PEG (such as depot steroid injection, laxative) • have history of idiopathic anaphylaxis • have experienced myocarditis or pericarditis determined as likely to be related to previous COVID-19 vaccination • are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for vaccination) • have received a full dose of COVID-19 vaccine in the preceding 21 days |
| Cautions, including any relevant action to be taken Continued over page | <p>Facilities for management of anaphylaxis should be available at all vaccination sites. Recipients of COVID-19 mRNA vaccine BNT162b2 should be kept for observation and monitored for a minimum of 15 minutes.</p> <p>Where individuals experienced a possible allergic reaction to a dose of COVID-19 vaccine follow the guidance in Chapter 14a of the Green Book</p> |

² Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required

³ Contains polyethylene glycol (PEG), refer to [Regulation 174 Information for UK Healthcare Professionals](#) for a full list of excipients.

Cautions, including any relevant action to be taken
(continued)

in relation to the administration of subsequent doses.

Individuals with non-allergic reactions (vasovagal episodes, non-urticarial skin reaction or non-specific symptoms) to a COVID-19 vaccine can receive subsequent doses of vaccine in any vaccination setting.

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Individuals with a bleeding disorder may develop a haematoma at the injection site. Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up to date with their scheduled INR testing and whose latest INR was below the upper threshold of their therapeutic range, can receive intramuscular vaccination. A fine needle (equal to 23 gauge or finer calibre such as 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. If in any doubt, consult with the clinician responsible for prescribing or monitoring the individual's anticoagulant therapy. The individual/parent/carer should be informed about the risk of haematoma from the injection.

Very rare reports have been received of Guillain-Barre Syndrome (GBS) following COVID-19 vaccination (further information is available in [Chapter 14a](#)). Healthcare professionals should be alert to the signs and symptoms of GBS to ensure correct diagnosis and to rule out other causes, in order to initiate adequate supportive care and treatment. Individuals who have a history of GBS should be vaccinated as recommended for their age and underlying risk status. In those who are diagnosed with GBS after the first dose of vaccine, the balance of risk benefit is in favour of completing a full COVID-19 vaccination schedule. On a precautionary basis, however, where GBS occurs within six weeks of an Astra Zeneca vaccine, for any future doses Pfizer or Moderna COVID-19 vaccines are preferred. Where GBS occurs following either of the mRNA vaccines, further vaccination can proceed as normal, once recovered.

Past history of COVID-19 infection

There is no convincing evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.

Vaccination of individuals who may be infected but asymptomatic or incubating COVID-19 infection is unlikely to have a detrimental effect on the illness. Vaccination should be deferred in those with confirmed infection to avoid confusing the differential diagnosis. As clinical deterioration can occur up to two weeks after infection, vaccination of adults and high risk children should be deferred until clinical recovery to around four weeks after onset of symptoms or four weeks from the first confirmed positive specimen in those who are asymptomatic. In younger people, protection from natural infection is likely to be high for a period of months, and vaccination in those recently infected may increase the chance of side effects. Therefore, vaccination should ideally be deferred till at least twelve weeks from onset (or sample date) in children and

Continued over page

| | |
|--|--|
| <p>Cautions, including any relevant action to be taken (continued)</p> | <p>young people under 18 years who are not in high risk groups (see the Dose and frequency of administration section). This includes children and young people who developed Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) and then become eligible for vaccination. Current advice in PIMS-TS cases suggests that an interval of 12 weeks should be observed, although earlier administration can be considered in those at risk of infection and/or who are fully recovered. Such earlier vaccination should be on a patient specific basis and is not covered by this PGD.</p> <p>Having prolonged COVID-19 symptoms is not a contraindication to receiving COVID-19 vaccine but if the individual is seriously debilitated, still under active investigation, or has evidence of recent deterioration, deferral of vaccination may be considered to avoid incorrect attribution of any change in the person's underlying condition to the vaccine.</p> <p>Vaccine Surveillance</p> <p>The UK regulator will maintain real-time surveillance post deployment of COVID-19 vaccines in the UK. In response to any safety signals, the Medicines and Healthcare products Regulatory Agency (MHRA) may provide temporary advice or make substantive amendments to the authorised conditions of the vaccine product's supply in the UK. Administration under this PGD must be in accordance with the most up-to-date advice or amendments (see Green Book Chapter 14a and Regulatory approval of Pfizer/BioNTech vaccine for COVID-19). These documents take precedence for the purposes of compliance with this PGD, if there is a delay in updating other provisions of this PGD that cut across them.</p> |
| <p>Action to be taken if the patient is excluded</p> <p>Continued over page</p> | <p>The risk to the individual of not being immunised must be considered. The indications for risk groups are not exhaustive, and the healthcare practitioner should consider the risk of COVID-19 exacerbating any underlying disease that an individual may have, as well as the risk of serious illness from COVID-19 itself. Where appropriate, such individuals should be referred for assessment of clinical risk. Where risk is identified as equivalent to those currently eligible for immunisation, vaccination may be provided by an appropriate prescriber or on a patient specific basis, under a PSD.</p> <p>For individuals who have had a previous systemic allergic reaction (including immediate onset anaphylaxis) to a previous dose of COVID-19 mRNA vaccine, or any component of the vaccine, advice should be sought from an allergy specialist.</p> <p>Special precautions as described in Chapter 14a, and consideration of the possibility of undiagnosed PEG-allergy, is required for individuals with:</p> <ul style="list-style-type: none"> • history of prior allergic reaction to COVID-19 vaccine that required medical intervention in hospital • history of immediate anaphylaxis to multiple, different drug classes, with the trigger unidentified (this may indicate PEG allergy) • history of anaphylaxis to a vaccine, injected antibody preparation or a medicine likely to contain PEG (such as depot steroid injection, laxative) • history of idiopathic anaphylaxis <p>Such individuals should not be vaccinated with COVID-19 mRNA vaccine BNT162b2, except on the expert advice of an allergy specialist and under a PSD.</p> <p>Individuals who have experienced myocarditis or pericarditis following COVID-19 vaccination should be assessed by an appropriate clinician to determine whether it is likely to be vaccine related. As the mechanism of</p> |

| | |
|---|--|
| <p>Action to be taken if the patient is excluded (continued)</p> | <p>action and risk of recurrence of myocarditis and pericarditis are being investigated, the current advice is that an individual's second or subsequent doses should be deferred pending further investigation. Following investigation any subsequent dose should be provided by an appropriate prescriber or on a patient specific basis, under a PSD.</p> <p>In case of postponement due to acute illness, advise when the individual can be vaccinated and if possible, ensure another appointment is arranged.</p> <p>Document the reason for exclusion and any action taken.</p> |
| <p>Action to be taken if the patient or carer declines treatment</p> | <p>Informed consent, from the individual or a person legally able to act on the person's behalf, must be obtained for each administration and recorded appropriately. Where a person lacks the capacity, in accordance with the Mental Capacity Act 2005, a decision to vaccinate may be made in the individual's best interests. For further information on consent see Chapter 2 of 'The Green Book'.</p> <p>Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications if not immunised.</p> <p>Document advice given and the decision reached.</p> |
| <p>Arrangements for referral</p> | <p>As per local policy.</p> |

5. Description of treatment

| | |
|---|---|
| <p>Name, strength and formulation of drug</p> | <p>COVID-19 mRNA vaccine BNT162b2 concentrate for solution for injection, presented as a multidose vial.</p> <p>1 vial (0.45ml) contains 6 doses of 30micrograms of tozinameran, a BNT162b2 RNA (embedded in lipid nanoparticles).</p> <p>Vials may alternatively be labelled:</p> <ul style="list-style-type: none"> • BNT162b2 (SARS-COV-2-mRNA vaccine), or • Pfizer-BioNTech COVID-19 vaccine <p>Note: Where appropriate to the delivery model, this PGD may also be used for the administration of vaccine that has been prepared (diluted) by another person in accordance with the manufacturer's instructions and Human Medicines Regulation 3A (UK Statutory Instrument 2020 No. 1594), that is prepared by or under the supervision of a doctor, a registered nurse or a pharmacist.</p> |
| <p>Legal category</p> | <p>COVID-19 mRNA vaccine BNT162b2 has been provided temporary authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for supply in the UK under regulation 174 and 174A of HMR 2012, see Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk).</p> <p>In accordance with the UK Statutory Instrument 2020 No. 1125, The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020, a PGD may now be used to supply and/or administer a medicine authorised under regulation 174.</p> <p>COVID-19 mRNA vaccine BNT162b2 is categorised as a prescription only medicine (POM).</p> <p>Note: For administration of Comirnaty COVID-19 mRNA vaccine, which has been granted a conditional marketing authorisation, see the Patient Group Direction for Comirnaty COVID-19 mRNA vaccine</p> |
| <p>Black triangle▼</p> | <p>As a new vaccine product, MHRA has a specific interest in the reporting of adverse drug reactions for this product.</p> |
| <p>Off-label use</p> | <p>COVID-19 mRNA vaccine BNT162b2 is supplied in the UK in accordance with regulation 174.</p> <p>As part of the consent process, healthcare professionals must inform the individual/parent/carer that this vaccine has been authorised for temporary supply in the UK by the regulator, MHRA, and that it is being offered in accordance with national guidance. The Regulation 174 Information for UK recipients for COVID-19 mRNA Vaccine BNT162b2 should be available to inform consent.</p> |
| <p>Route / method of administration</p> <p>Continued over page</p> | <p>COVID-19 mRNA vaccine BNT162b2 is for administration by intramuscular injection only, preferably into deltoid region of the upper arm.</p> <p>Using aseptic technique, thawed COVID-19 mRNA vaccine BNT162b2 requires dilution in its original vial with 1.8ml of unpreserved sodium chloride 0.9% solution for injection, prior to withdrawing a 0.3ml dose for administration.</p> <p>Vaccine should be prepared in accordance with the manufacturer's recommendations (see Regulation 174 Information for UK Healthcare Professionals) and NHS standard operating procedures for the service. Gently invert the diluted solution 10 times. Do not shake the vaccine.</p> |

| | |
|---|--|
| <p>Route / method of administration (continued)</p> | <p>Inspect visually prior to administration and ensure appearance is consistent with the description in the Regulation 174 Information for UK Healthcare Professionals, that is an off-white solution with no particulates visible. Discard the vaccine if particulates or discolouration are present.</p> <p>Check product name, batch number and expiry date prior to administration.</p> <p>In order to extract at least 6 doses from a single vial, low dead-volume syringes and/or needles should be used. Each dose must contain 0.3ml of vaccine. If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3ml, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials. Any unused vaccine should be discarded 6 hours after dilution.</p> |
| <p>Dose and frequency of administration</p> <p>Continued over page</p> | <p>A dose of COVID-19 mRNA vaccine BNT162b2 is 0.3ml and contains 30micrograms of COVID-19 mRNA vaccine in 0.3ml.</p> <p>The two-dose primary course consists of 30micrograms in 0.3ml followed, after an interval of at least 21 days, by a second dose of 30micrograms in 0.3ml. However, the programme schedule, including both the number of doses and the intervals between them, should be administered in accordance with official national guidance which is set out in Chapter 14a of the Green Book and summarised below and in a table at Appendix A.</p> <p>For both adenovirus vector and mRNA vaccines, there is evidence of better immune response and/or protection where longer intervals between doses in the primary schedule are used.</p> <p>Based on this evidence, longer intervals are likely to provide more durable protection. JCVI is currently recommending a minimum interval of eight weeks between doses of all the available COVID-19 vaccines where a two-dose primary schedule is used for adults and for children at high risk. Operationally, this consistent interval should be used for all vaccines with a two-dose primary schedule to avoid confusion and simplify booking and will help to ensure a good balance between achieving rapid and long-lasting protection.</p> <p>For those under 18 years who are not in a high risk group a 12-week interval is preferred (see below and Appendix A). This is based on precautionary advice from the JCVI based on emerging evidence of a lower rate of myocarditis in countries that use a longer schedule.</p> <p>The main exception to the eight-week lower interval would be those about to commence immunosuppressive treatment. In these individuals, the licensed minimal interval of at least 21 days may be followed to enable the vaccine to be given whilst their immune system is better able to respond.</p> <p>If an interval longer than the recommended interval is left between doses, the second dose should still be given (using the same vaccine as was given for the first dose if possible, see Additional Information). The course does not need to be restarted.</p> <p>Interval post SARS-CoV-2 infection</p> <p>For individuals who have had proven SARS-CoV-2 infection (see Cautions), any subsequent COVID-19 vaccination should ideally be deferred until:</p> <ul style="list-style-type: none"> • at least twelve weeks from onset (or sample date) for those under 18 years of age who are not in a risk group • at least four weeks from onset (or sample date) for individuals in a risk group and all those over 18 years of age <p>Administration at intervals less than this is not covered by this PGD.</p> |

Dose and frequency of administration
(continued)

Primary course for individuals at higher risk

The primary course for individuals at higher risk is recommended to be scheduled as follows:

- individuals 12 years and over sharing living accommodation with an immunosuppressed individual of any age should receive a two-dose primary course at a recommended 8-week minimum interval
- individuals 12 years and over in an at-risk group⁴ and those from 16 years of age working in health and social care should receive a two-dose primary course at a recommended 8-week minimum interval. A third primary dose is recommended for those who have severe immunosuppression in proximity to their first or second COVID-19 doses.
- individuals 12 years and over who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule should receive a three-dose primary course at a recommended 8-week minimum interval (see 'Box: Criteria for a third primary dose of COVID-19 vaccine' in [Chapter 14a](#)). The decision on the timing of the third dose should be undertaken by the specialist involved in the care of the individual. The third dose should be given ideally at least 8 weeks after the second dose, with special attention paid to current or planned immunosuppressive therapies (see [Additional information](#) section). This group of individuals will also require a booster dose to extend protection from their primary course. Boosters are expected to be required from six months after the third dose, although JCVI will advise on optimal timing after evidence from trials in these populations become available.

Individuals who are not at higher risk

The primary course for individuals who are not at higher risk is recommended to be scheduled as follows:

- individuals 12 to 15 years of age and not in a recognised risk group can receive their first dose, as recommended by the Chief Medical Officers. A decision on when to offer the second dose to healthy children is pending further evidence on the safety of a second dose in this age group
- individuals 16 and 17 years of age and not in a recognised risk group nor working in health and social care should receive a two-dose primary course at a recommended 12-week minimum interval⁵
- individuals 18 years of age and over and not in a recognised risk group should receive a two-dose primary course at a recommended 8-week minimum interval

Booster vaccination

A booster (third) dose should be offered to individuals eligible for a booster (third) dose as part of the national COVID-19 vaccination programme in accordance with the recommendations from the [JCVI](#) and [Chapter 14a](#) of the Green Book.

The JCVI is recommending that booster vaccines are scheduled at a six-month interval from completing the primary course. This interval will automatically help to prioritise older and more vulnerable patients.

For operational reasons, administration may be brought forward to a minimum of five months in certain circumstances including:

Continued over page

⁴ At risk groups are listed in the Green Book [Chapter 14a](#) (Table 3 for individuals 16 years of age and over and Table 4 for children aged 12-15 years).

⁵ There will be a transitional period where this PGD can be used to administer second doses for those from 17 years and 9 months of age (not in a risk group) who have an existing second dose appointment booked at 8 weeks.

| | |
|--|---|
| Dose and frequency of administration (continued) | <ul style="list-style-type: none"> • in a care home setting to enable all residents to be vaccinated in the same session • where an otherwise eligible individual attends for another reason (for example to receive influenza vaccine) <p>For those about to receive immunosuppressive treatment the booster may be brought forward to a minimum of four months (~120 days) to avoid giving the booster when the immune system is less able to respond.</p> |
| Duration of treatment | See Dose and frequency of administration above. |
| Quantity to be supplied / administered | Administer 30micrograms in 0.3ml per dose |
| Supplies | <p>Providers should order/receive COVID-19 vaccines via the national appointed supply route for the provider.</p> <p>NHS standard operating procedures should be followed for appropriate ordering, storage, handling, preparation, administration and waste minimisation of COVID-19 mRNA Vaccine BNT162b2, which ensure use is in accordance with Regulation 174 Information for UK Healthcare Professionals and Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine BNT162b2.</p> |
| Storage | <p>COVID-19 mRNA vaccine BNT162b2 is supplied from the manufacturer as a multiple-dose vial of frozen, preservative-free concentrate, which requires storage in an ultra-low temperature freezer at -80°C to -60°C or a thermal container at -90°C to -60°C.</p> <p>Shelf life is 9 months at -80°C to -60°C.</p> <p>Store in original packaging in order to protect from light.</p> <p>The undiluted vaccine can be stored for up to 1 month (31 days) at 2°C to 8°C, or up to 2 hours at temperatures up to 25°C, prior to use.</p> <p>During storage, minimise exposure to room light, and avoid exposure to direct sunlight and ultraviolet light. Thawed vials can be handled in room light conditions.</p> <p>Once thawed the vaccine cannot be re-frozen.</p> <p>After aseptic dilution, vials should be marked with the dilution date and time, stored at 2°C to 25°C and used as soon as practically possible and within 6 hours from the time of dilution. The vaccine does not contain preservative.</p> <p>Once the dose is drawn from the vial it should be administered immediately.</p> <p>The above details relate to storage requirements and available stability data at the time of product authorisation. This may be subject to amendment as more data becomes available. Refer to NHS standard operating procedures for the service and the most up to date manufacturer's recommendations in the Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine BNT162b2 and Regulation 174 Information for UK Healthcare Professionals.</p> |
| Disposal | <p>Follow local clinical waste policy and NHS standard operating procedures and ensure safe and secure waste disposal.</p> <p>Equipment used for vaccination, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of safely and securely according to local authority arrangements and</p> |
| Continued over page | |

| | |
|---|--|
| Disposal (continued) | guidance in the technical memorandum 07-01 : Safe management of healthcare waste (Department of Health, 2013). |
| Drug interactions | <p>Immunological response may be diminished in those receiving immunosuppressive treatment, but it is important to still immunise this group.</p> <p>Although no data for co-administration of COVID-19 vaccine with other vaccines exists, in the absence of such data, first principles would suggest that interference between inactivated vaccines with different antigenic content is likely to be limited. Based on experience with other vaccines, any potential interference is most likely to result in a slightly attenuated immune response to one of the vaccines. There is no evidence of any safety concerns, although it may make the attribution of any adverse events more difficult. Similar considerations apply to co-administration of inactivated (or non-replicating) COVID-19 vaccines with live vaccines such as MMR. In particular, live vaccines which replicate in the mucosa, such as live attenuated influenza vaccine (LAIV) are unlikely to be seriously affected by concomitant COVID-19 vaccination.</p> <p>A seven-day interval should ideally be observed between COVID-19 vaccination and shingles vaccination. This is based on the potential for an inflammatory response to COVID-19 vaccine to interfere with the response to the live virus in the older population and because of the potential difficulty of attributing systemic side effects to the newer adjuvanted shingles vaccine.</p> <p>For further information about co-administration with other vaccines see Additional Information section.</p> |
| Identification and management of adverse reactions | <p>The most frequent adverse reactions in individuals 16 years of age and older are injection site pain, fatigue, headache, myalgia, chills, arthralgia, pyrexia and injection site swelling. These reactions are usually mild or moderate in intensity and resolve within a few days after vaccination. Redness at the injection site, nausea and vomiting are reported as common. Lymphadenopathy is reported with a frequency of less than 1%.</p> <p>The most frequent adverse reactions in individuals 12 to 15 years of age are injection site pain, fatigue, headache, myalgia, chills, arthralgia and pyrexia.</p> <p>There have been very rare reports of myocarditis and pericarditis occurring after vaccination with COVID-19 mRNA vaccine BNT162b2 often in younger men and shortly after the second dose of the vaccine. These are typically mild cases and individuals tend to recover within a short time following standard treatment and rest. Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis. Vaccinated individuals should also seek immediate medical attention should they experience new onset of chest pain, shortness of breath, palpitations or arrhythmias.</p> <p>Individuals should be provided with the advice within the leaflet What to expect after your COVID-19 vaccination, which covers the reporting of adverse reactions and their management, such as with analgesic and/or antipyretic medication.</p> <p>Vaccinated individuals should be advised that the COVID-19 vaccine may cause a mild fever, which usually resolves within 48 hours. This is a common, expected reaction and isolation is not required unless COVID-19 is suspected.</p> <p>A detailed list of adverse reactions is available in the Regulation 174 Information for UK Healthcare Professionals</p> |

| | |
|--|--|
| <p>Reporting procedure of adverse reactions</p> | <p>Healthcare professionals and individuals/carers should report suspected adverse reactions to the MHRA using the Coronavirus Yellow Card reporting scheme or search for MHRA Yellow Card in the Google Play or Apple App Store.</p> <p>As a new vaccine product, MHRA has a specific interest in the reporting of all adverse drug reactions for this product.</p> <p>Any adverse reaction to a vaccine should also be documented in the individual's record and the individual's GP should be informed.</p> <p>The Green Book Chapter 14a and Chapter 8 provide further details regarding the clinical features of reactions to be reported as 'anaphylaxis'. Allergic reactions that do not include the clinical features of anaphylaxis should be reported as 'allergic reaction'.</p> |
| <p>Written information to be given to patient or carer</p> | <p>Ensure the individual has been provided appropriate written information such as the:</p> <ul style="list-style-type: none"> • Regulation 174 Information for UK recipients for COVID-19 mRNA vaccine BNT162b2 • COVID-19 Vaccination Record Card • What to expect after your COVID-19 vaccination • COVID-19 vaccination: women of childbearing age, currently pregnant, or breastfeeding • COVID-19 vaccination: a guide to booster vaccination |
| <p>Patient advice / follow up treatment</p> | <p>Vaccine recipients should be monitored for 15 mins after vaccination, with a longer observation period when indicated after clinical assessment (see Chapter 14a).</p> <p>Inform the individual/parent/carer of possible side effects and their management.</p> <p>The individual/parent/carer should be advised to seek appropriate advice from a healthcare professional in the event of an adverse reaction.</p> <p>Vaccinated individuals should be advised to seek immediate medical attention should they experience new onset of chest pain, shortness of breath, palpitations or arrhythmias.</p> <p>Advise the individual/parent/carer that they can report side effects directly via the national reporting system run by the MHRA known as the Coronavirus Yellow Card reporting scheme or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, they can help provide more information on the safety of medicines.</p> <p>As with all vaccines, immunisation may not result in protection in all individuals. Immunosuppressed individuals should be advised that they may not make a full immune response to the vaccine. Nationally recommended protective measures should still be followed.</p> <p>When applicable, advise the individual/parent/carer when to return for vaccination or when a subsequent vaccine dose is due.</p> |
| <p>Special considerations / additional information</p> <p>Continued over page</p> | <p>Ensure there is immediate access to an anaphylaxis pack including adrenaline (epinephrine) 1 in 1,000 injection and easy access to a telephone at the time of vaccination.</p> <p>Minor illnesses without fever or systemic upset are not valid reasons to postpone vaccination. If an individual is acutely unwell, vaccination should be postponed until they have fully recovered. This is to avoid confusing the differential diagnosis of any acute illness (including COVID-19) by wrongly attributing any signs or symptoms to the adverse effects of the vaccine.</p> |

Special considerations / additional information
(continued)

Pregnancy

Vaccination in pregnancy should be offered in accordance with recommendations in [Chapter 14a](#), following a discussion of the risks and benefits of vaccination with the woman. Although clinical trials on the use of COVID-19 vaccines during pregnancy are not advanced, the available data do not indicate any harm to pregnancy. JCVI has therefore advised that women who are pregnant should be offered vaccination at the same time as non-pregnant women, based on their age and clinical risk group. There is extensive post-marketing experience of the use of the Pfizer BioNTech and Moderna vaccines in the USA with no safety signals so far. Over 80,000 women now report having been vaccinated whilst pregnant or when they might be pregnant in England. Because of wider experience with mRNA vaccines, these are currently the preferred vaccines to offer to pregnant women.

Routine questioning about last menstrual period and/or pregnancy testing is not required before offering the vaccine. Women who are planning pregnancy or in the immediate postpartum should be vaccinated with a suitable product for their age and clinical risk group.

If a woman finds out she is pregnant after she has started a course of vaccine, she should complete vaccination during pregnancy using the same vaccine product (unless contra-indicated).

Breastfeeding

There is no known risk associated with being given a non-live vaccine whilst breastfeeding. JCVI advises that breastfeeding women may be offered any suitable COVID-19 vaccine. Emerging safety data is reassuring: mRNA was not detected in the breast milk of recently vaccinated women and protective antibodies have been detected in breast milk.

The developmental and health benefits of breastfeeding are clear and should be discussed with the woman, along with her clinical need for immunisation against COVID-19.

Previous incomplete vaccination

If the course is interrupted or delayed, it should be resumed using the same vaccine but the earlier doses should not be repeated. Evidence suggests that those who receive mixed schedules, including mRNA and adenovirus vectored vaccines make a good immune response, although rates of side effects at the second dose are higher. Therefore, every effort should be made to determine which vaccine the individual received and to complete the course with the same vaccine. For individuals who started the schedule and who attend for vaccination at a site where the same vaccine is not available or considered suitable, or if the first product received is unknown, it is reasonable to offer one dose of the locally available product to complete the primary schedule. This option is preferred if the individual is likely to be at immediate high risk or is considered unlikely to attend again. In these circumstances, this PGD may be used.

Individuals who experience severe expected reactions after a first dose of AstraZeneca or Pfizer COVID-19 vaccines appear to have a higher rate of such reactions when they receive a second dose of the alternate vaccine. Therefore, individuals who have received a first dose of the AstraZeneca vaccine should complete the primary course with the same vaccine, with the exception of those who experienced an episode of anaphylaxis, thrombosis and thrombocytopenia syndrome or GBS.

Continued over page

For individuals with a history of thrombosis combined with thrombocytopenia following vaccination with the AstraZeneca COVID-19

Special considerations / additional information
(continued)

vaccine, current evidence would support completion of the course with an mRNA vaccine, provided a period of at least 12 weeks has elapsed since the dose of AstraZeneca vaccine.

Individuals with a history of capillary leak syndrome should be carefully counselled about the risks and benefits of vaccination. An alternative vaccine to the AstraZeneca COVID-19 vaccine, such as COVID-19 mRNA vaccine BNT162b2, may be offered to complete a vaccination course.

Individuals who are participating in a clinical trial of COVID-19 vaccines who present for vaccination should be referred back to the investigators. Eligible persons who are enrolled in vaccine trials should then be provided with written advice on whether and when they should be safely vaccinated in the routine programme. Advice should also be provided from the trial investigators on whether any individual could receive additional doses for the purposes of vaccine certification. Trial participants who are eligible for boosters should be offered vaccination in line with the general population, six months after the dose considered as the final primary dose or the final revaccination (if the latter is required for certification purposes).

Individuals who have been vaccinated abroad are likely to have received an mRNA or vector vaccine based on the spike protein, or an inactivated whole viral vaccine. Specific advice on [Vaccination of those who received COVID-19 vaccine overseas](#) is available from the UKHSA.

Co-administration with other vaccines

Where individuals in an eligible cohort present having recently received one or more inactivated or live vaccines, COVID-19 vaccination should still be given. The same applies for most other live and inactivated vaccines where COVID-19 vaccination has been received first or where an individual presents requiring two or more vaccines. It is generally better for vaccination to proceed and it may be provided under this PGD, to avoid any further delay in protection and to avoid the risk of the individual not returning for a later appointment. This includes but is not limited to vaccines commonly administered around the same time or in the same settings (including influenza and pneumococcal polysaccharide vaccine in those aged over 65 years, pertussis-containing vaccines and influenza vaccines in pregnancy, and LAIV, HPV, MenACWY and Td-IPV vaccines in the schools programmes). The only exceptions to this are the shingles vaccines, where a seven-day interval should ideally be observed. This is based on the potential for an inflammatory response to COVID-19 vaccine to interfere with the response to the live virus in the older population and because of the potential difficulty of attributing systemic side effects to the newer adjuvanted shingles vaccine.

A UK study of co-administration of AstraZeneca and Pfizer BioNTech COVID-19 vaccines with inactivated influenza vaccines confirmed acceptable immunogenicity and reactogenicity. Where co-administration does occur, individuals should be informed about the likely timing of potential adverse events relating to each vaccine. If the vaccines are not given together, they can be administered at any interval, although separating the vaccines by a day or two will avoid confusion over systemic side effects.

Non-responders / immunosuppressed

Immunological response may be lower in immunocompromised individuals, but they should still be vaccinated.

JCVI advises that a third primary vaccine dose be offered to individuals aged 12 years and over who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule (see 'Box: Criteria for a third primary dose of COVID-19 vaccine' in [Chapter 14a](#)). Most individuals whose immunosuppression commenced at least two

Continued over page

| | |
|---|---|
| <p>Special considerations / additional information (continued)</p> | <p>weeks after the second dose of vaccination do not require an additional primary vaccination at this stage.</p> <p>The decision on the timing of the third primary dose should be undertaken by the specialist involved in the care of the individual. In general, vaccines administered during periods of minimum immunosuppression (where possible) are more likely to generate better immune responses.</p> <p>Individuals who have received a bone marrow transplant after vaccination should be considered for a re-immunisation programme for all routine vaccinations and for COVID-19 (see Chapter 7 of the Green Book). This is not covered by this PGD and should be provided on a patient specific basis.</p> |
| <p>Records</p> | <p>Record:</p> <ul style="list-style-type: none"> • that valid informed consent was given or a decision to vaccinate made in the individual’s best interests in accordance with the Mental Capacity Act 2005 • name of individual, address, date of birth and GP with whom the individual is registered (or record where an individual is not registered with a GP) • name of immuniser • name and brand of vaccine • date of administration • dose, form and route of administration of vaccine • quantity administered • batch number and expiry date • anatomical site of vaccination • advice given, including advice given if excluded or declines vaccination • details of any adverse drug reactions and actions taken • supplied via PGD <p>All records should be clear, legible and contemporaneous.</p> <p>As a variety of COVID-19 vaccines are available, it is especially important that the exact brand of vaccine, batch number and site at which each vaccine is given is accurately recorded in the individual’s records.</p> <p>It is important that vaccinations are recorded in a timely manner on appropriate health care records for the individual. Systems should be in place to ensure this information is returned to the individual’s general practice record in a timely manner to allow clinical follow up and to avoid duplicate vaccination.</p> <p>A record of all individuals receiving treatment under this PGD should also be kept for audit purposes.</p> |

6. Key references

| | |
|-----------------------|--|
| Key references | <p>COVID-19 mRNA vaccine BNT162b2 vaccination</p> <ul style="list-style-type: none">• Immunisation Against Infectious Disease: The Green Book, Chapter 14a. Updated 15 November 2021. https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book• COVID-19 vaccination programme. Updated 15 November 2021. https://www.gov.uk/government/collections/covid-19-vaccination-programme• Training recommendations for COVID-19 vaccinators. Published 4 October 2021. https://www.gov.uk/government/publications/covid-19-vaccinator-training-recommendations/training-recommendations-for-covid-19-vaccinators• National COVID-19 vaccination e-learning programme. https://www.e-lfh.org.uk/programmes/covid-19-vaccination/• COVID-19 vaccinator competency assessment tool. Updated 16 March 2021 https://www.gov.uk/government/publications/covid-19-vaccinator-competency-assessment-tool• COVID-19: vaccination programme guidance for healthcare practitioners. Updated 6 August 2021 https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners• Regulation 174 Information for UK Healthcare Professionals and Regulation 174 Information for UK recipients for COVID-19 mRNA vaccine BNT162b2 and Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine BNT162b2. Updated 15 November 2021 https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19 <p>General</p> <ul style="list-style-type: none">• Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Department of Health 20 March 2013 https://www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-hm-07-01/• NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published March 2017. https://www.nice.org.uk/guidance/mpg2• NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. Updated March 2017. https://www.nice.org.uk/guidance/mpg2/resources• Patient Group Directions: who can use them. Medicines and Healthcare products Regulatory Agency. 4 December 2017. https://www.gov.uk/government/publications/patient-group-directions-pgds/patient-group-directions-who-can-use-them• UK Statutory Instrument 2012 No. 1916, The Human Medicines Regulations 2012 https://www.legislation.gov.uk/ukSI/2012/1916/contents• UK Statutory Instrument 2020 No. 1125, The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 https://www.legislation.gov.uk/ukSI/2020/1125/contents/made• UK Statutory Instrument 2020 No. 1594, The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 https://www.legislation.gov.uk/ukSI/2020/1594/regulation/4/made |
|-----------------------|--|

7. Practitioner authorisation sheet

COVID-19 mRNA vaccine BNT162b2 PGD v06.00

Valid from: 19/11/2021 Expiry: 31/03/2022

By signing this PGD you are indicating that you agree to its contents and that you will work within it.

PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.

| Name | Designation | Signature | Date |
|------|-------------|-----------|------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Authorising manager

I confirm that the registered healthcare professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of

insert name of organisation

for the above named healthcare professionals who have signed the PGD to work under it.

| Name | Designation | Signature | Date |
|------|-------------|-----------|------|
| | | | |

Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

APPENDIX A (Read in conjunction with [Dose and frequency of administration](#) section)

Recommended primary dose schedule by age and risk status.

| Primary course for individuals at higher risk | | | |
|---|--------------|---|---|
| Age | Doses | Advised Minimum Interval⁶ | Recommendations |
| 12 years and over sharing living accommodation with an immunosuppressed individual of any age | Two | 8 weeks | |
| 12 years and over in an at-risk group ⁷ and those from 16 years of age working in health and social care. | Two | 8 weeks | Note: A third primary dose is recommended for those who have severe immunosuppression in proximity to their first or second COVID-19 doses. |
| 12 years and over who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule | Three | 8 weeks | The decision on the timing of the third dose should be undertaken by the specialist involved in the care of the individual. The third dose should be given ideally at least 8 weeks after the second dose, with special attention paid to current or planned immunosuppressive therapies (see Additional information section). This group of individuals will also require a booster dose to extend protection from their primary course. Boosters are expected to be required from six months after the third dose, although JCVI will advise on optimal timing after evidence from trials in these populations become available. |
| Individuals who are not at higher risk | | | |
| 12 to 15 years of age and not in a recognised risk group ⁷ | One | Not applicable | The Chief Medical Officers have recommended that all young people aged 12 to 15 years can receive their first dose of COVID-19 vaccine. A decision on when to offer the second dose to healthy children is pending further evidence on the safety of a second dose in this age group. |
| 16 and 17 years of age and not in a recognised risk group ⁷ nor working in health and social care | Two | 12 weeks ⁸ | |
| 18 years and over and not in a recognised risk group | Two | 8 weeks | |

⁶ For individuals who have had proven SARS-CoV-2 infection (see [Cautions](#)), vaccination should ideally be deferred until:

- at least twelve weeks from onset (or sample date) for those under 18 years of age who are not in a risk group
- at least four weeks from onset (or sample date) for individuals in a risk group and all those over 18 years of age

⁷ At risk groups are listed in the Green Book [Chapter 14a](#) (Table 3 for individuals 16 years of age and over and Table 4 for children aged 12-15 years).

⁸ There will be a transitional period where this PGD can be used to administer second doses for those from 17 years and 9 months of age (not in a risk group) who have an existing second dose appointment booked at 8 weeks.